{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:17:00Z","timestamp":1786987020698,"version":"build-2736575974"},"reference-count":23,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.clml.2020.08.030","type":"journal-article","created":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T11:18:16Z","timestamp":1600514296000},"page":"e994-e997","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Daratumumab-induced Choroidal Effusion: A Case Report and Review of the Literature"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6017-8722","authenticated-orcid":false,"given":"Anne","family":"Strong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Huvard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6996-0497","authenticated-orcid":false,"given":"Tomer","family":"Mark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Capitena Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.08.030_bib1","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1634\/theoncologist.2017-0229","article-title":"FDA approval summary: daratumumab for treatment of multiple myeloma after one prior therapy","volume":"22","author":"Bhatnagar","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2020.08.030_bib2","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.08.030_bib3","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.clml.2017.06.030","article-title":"Monoclonal antibodies in multiple myeloma: a new wave of the future","volume":"17","author":"Sherbenou","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.08.030_bib4","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1200\/JOP.18.00143","article-title":"Managing infusion reactions to new monoclonal antibodies in multiple myeloma: daratumumab and elotuzumab","volume":"14","author":"Nooka","year":"2018","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.clml.2020.08.030_bib5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","article-title":"Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.030_bib6","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1182\/blood.V128.22.2142.2142","article-title":"Use of montelukast to reduce infusion reactions in an early access treatment protocol of daratumumab in United States Patients with relapsed or refractory multiple myeloma","volume":"128","author":"Chari","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.030_bib7","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1097\/IJG.0000000000001562","article-title":"Bilateral secondary angle closure during daratumumab infusion: a case report and review of the literature","volume":"29","author":"Edwards","year":"2020","journal-title":"J\u00a0Glaucoma"},{"key":"10.1016\/j.clml.2020.08.030_bib8","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1097\/IJG.0000000000000995","article-title":"Bilateral angle closure following the infusion of a monoclonal antibody to treat relapsing multiple myeloma","volume":"27","author":"Lee","year":"2018","journal-title":"J\u00a0Glaucoma"},{"key":"10.1016\/j.clml.2020.08.030_bib9","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajoc.2018.12.017","article-title":"Daratumumab-induced transient myopic shift","volume":"13","author":"Mavrommatis","year":"2019","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.clml.2020.08.030_bib10","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jamaophthalmol.2019.1427","article-title":"Association of choroidal effusion and infusion of daratumumab","volume":"137","author":"Rasmussen","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.clml.2020.08.030_bib11","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.08.030_bib12","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/eye.2013.41","article-title":"Acute cilio-choroidal effusion due to acetazolamide: unusual posterior involvement (OCT aspects)","volume":"27","author":"Malagola","year":"2013","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.clml.2020.08.030_bib13","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3341\/kjo.2011.25.3.214","article-title":"Acute-onset bilateral myopia and ciliochoroidal effusion induced by hydrochlorothiazide","volume":"25","author":"Roh","year":"2011","journal-title":"Korean J Ophthalmol"},{"key":"10.1016\/j.clml.2020.08.030_bib14","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0002-9394(14)72174-9","article-title":"Choroidal effusion as a mechanism for transient myopia induced by hydrochlorothiazide and triamterene","volume":"120","author":"S\u00f6ylev","year":"1995","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clml.2020.08.030_bib15","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1136\/bjo.87.5.648","article-title":"Topiramate induced myopic shift and angle closure glaucoma","volume":"87","author":"Chen","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.clml.2020.08.030_bib16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0002-9394(03)00774-8","article-title":"Mechanism of topiramate-induced acute-onset myopia and angle closure glaucoma","volume":"137","author":"Craig","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clml.2020.08.030_bib17","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000330860","article-title":"Massive bilateral choroidal detachment induced by administration of topiramate","volume":"2","author":"Dehghani","year":"2011","journal-title":"Case Rep Ophthalmol"},{"key":"10.1016\/j.clml.2020.08.030_bib18","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1097\/IJG.0000000000000157","article-title":"Bilateral angle closure following use of a weight loss combination agent containing topiramate","volume":"24","author":"Grewal","year":"2015","journal-title":"J\u00a0Glaucoma"},{"key":"10.1016\/j.clml.2020.08.030_bib19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12886-019-1230-y","article-title":"Angiographic features of drug-induced bilateral angle closure and transient myopia with ciliochoroidal effusion","volume":"19","author":"Kang","year":"2019","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.clml.2020.08.030_bib20","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/cxo.12685","article-title":"Topiramate-induced secondary angle closure: salient points in management","volume":"101","author":"Lam","year":"2018","journal-title":"Clin Exp Optom"},{"key":"10.1016\/j.clml.2020.08.030_bib21","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1007\/s10792-017-0740-y","article-title":"Bilateral acute angle closure glaucoma and myopic shift by topiramate-induced ciliochoroidal effusion: case report and literature review","volume":"38","author":"Lan","year":"2018","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.clml.2020.08.030_bib22","first-page":"1775","article-title":"Ciliochoroidal effusion syndrome induced by sulfa derivatives","volume":"120","author":"Ikeda","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.clml.2020.08.030_bib23","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/eye.1996.21","article-title":"Drug-induced ciliary body oedema: a new theory","volume":"10","author":"Krieg","year":"1996","journal-title":"Eye (Lond)"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502030522X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502030522X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:34:57Z","timestamp":1761870897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502030522X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S215226502030522X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.08.030","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Daratumumab-induced Choroidal Effusion: A Case Report and Review of the Literature","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.08.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}